HLA Loss Facilitates Immune Escape.
Researchers have developed a new software tool, called LOHHLA, which can pinpoint allele-specific HLA loss in tumors. When applied to a cohort of patients with non-small cell lung cancer, this genomic event was detected in 40% of cases, increasing in frequency as the disease spread to the brain.